Edition:
United States

Ampio Pharmaceuticals Inc (AMPE.A)

AMPE.A on American Stock Exchange

0.81USD
12:30pm EDT
Change (% chg)

$-0.01 (-0.77%)
Prev Close
$0.82
Open
$0.82
Day's High
$0.85
Day's Low
$0.79
Volume
7,139
Avg. Vol
43,488
52-wk High
$4.19
52-wk Low
$0.54

AMPE.A

Chart for AMPE.A

About

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for... (more)
No analyst recommendations are available for AMPE.A.

Overall

Beta: 0.26
Market Cap(Mil.): $46.73
Shares Outstanding(Mil.): 57.24
Dividend: --
Yield (%): --

Financials

  AMPE.A Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -0.26 -- --
ROI: -104.97 2.29 -5.84
ROE: -124.68 0.06 -5.23

BRIEF-Ampio Pharmaceuticals files for non-timely 10-Q

* Ampio Pharmaceuticals says intends to file form 10-Q as soon as practicable, but no later than May 15, 2017 Source text for Eikon: Further company coverage:

May 11 2017

BRIEF-Ampio Pharmaceuticals files for mixed shelf of up to $100 mln

* In addition, 5.0 million shares of co's common stock offered by the selling stockholder Source text (http://bit.ly/2okuxNM) Further company coverage:

Mar 31 2017

BRIEF-Ampio Pharmaceuticals amends warrant agreement

* Ampio Pharmaceuticals- entered into waiver, consent letter agreement with CVI Investments amending terms of warrants previously issued to CVI on Sept. 1, 2016

Mar 28 2017

BRIEF-Ampio pharmaceuticals provides corporate update

* Ampio pharmaceuticals - plans to advance all necessary biologic license application activities in parallel to expedite path to potential FDA approval

Mar 20 2017

BRIEF-Ampio receives guidance from the FDA

* Ampio receives guidance from the FDA and proposes a path for approval for single-injection ampion™ for the treatment of pain due to severe osteoarthritis of the knee

Feb 27 2017

More From Around the Web

Competitors

Earnings vs. Estimates